Depo-Medrol®

Dating:

Shelf-life up to 3 years, depending on strength5

Features:

Available in multiple strengths (multi-dose and single-dose vials), some of which are gluten free
View Features

Leadership and Excellence in Manufacturing
For 60 years, our goal has been to provide clinicians with a consistent supply of Depo-Medrol (methylprednisolone acetate injectable suspension, USP), with therapeutic options that meet the needs of many patients
Targeted Anti-Inflammatory Relief
Depo-Medrol® may be administered intramuscularly, intra-articularly, periarticularly, intrabursally, into the tendon sheath, or via intralesional injections at local site of inflammation. Dosage must be individualized and depends on the condition being treated and its severity. The frequency of intramuscular injections should be determined by the duration of clinical response7
Indications

When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Depo-Medrol Sterile Aqueous Suspension is indicated as follows:

  • Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions.
  • Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
  • Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
  • Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
  • Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.
  • Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
  • Neoplastic Diseases: For palliative management of leukemias and lymphomas.
  • Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
  • Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
  • Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.
  • Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
  • Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

(See WARNINGS) Depo-Medrol is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Depo-Medrol is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. Depo-Medrol also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

REFERENCES
1. Growth Dynamics Audit from September 2013 to September 2017. NSP Audit from October 2011 to September 2017. IMS Health. 2017
2. Methylprednisolone 2012-2017. IMS Health. 2017
3. National Library of Medicine. Daily Med: Current Clinical Information. SOLU-MEDROL label. Pharmacia and Upjohn Company. https://dailymed.nlm.nih.gov/dailymed/ getFile.cfm?setid=cd99be87-c8d9-48d6-a8e5-e081052e3f19&type=pdf&name=cd99be87-c8d9-48d6-a8e5-e081052e3f19. Accessed November 27, 2017.
4. National Library of Medicine. Daily Med: Current Clinical Information. DEPO-MEDROL label. Pharmacia and Upjohn Company. https://dailymed.nlm.nih.gov/dailymed/ getFile.cfm?setid=9a7b3837-e038-48bf-97e9-78ad463760dc&type=pdf&name=9a7b3837-e038-48bf-97e9-78ad463760dc. Accessed November 27, 2017.
5. Data on File. Pfizer Inc, New York, NY.
6. USPI Solu-Medrol®. New York, NY: Pfizer, Inc. 2018
7. USPI Depo-Medrol®. New York, NY: Pfizer, Inc. 2018